Announcement of the Consolidated Financial Statements for the second quarter of 2022 were approved by the Board of Directors

Announcement on behalf of subsidiary, Obigen Pharma Inc., that BOD resolved the Term Sheet for licensing of OBI-858 in China

SUPPLEMENTARY STATEMENTS ON NEWS ARTICLE

The Company announces discontinuation of the Phase II Study of OBI-888

Announcement of the status of implementation of the commitments during the up-listing at Taipei Exchange

The Company’s Board of Directors nominated Michael Chang to serve as the Chairman of the Board

Announcement of 2022 shareholders' meeting resolution to lift the non-competition restrictions for new directors

Announcement of 5th Remuneration Committee Members

Announcement of 4th Audit Committee Members

Announcement of Re-election of directors at the 2022 annual shareholders’ meeting